Abstract
Polynuclear compounds are a relatively new and successful approach in metal-based cancer chemotherapy as typified by the trinuclear Pt compound BBR3464 which was evaluated in clinical trials. In this review, we discuss newer developments of polynuclear ruthenium, osmium and gold complexes, focusing on their anticancer activity. The compounds presented are often supposed to exert their anticancer activity by different modes of action as compared to established drugs, including newly proposed mechanisms such as enzyme inhibition, crosslinking of biomacromolecules or through photo-activation, though many of the examples are also capable of binding to DNA nucleobases. Important metabolization and chemical characteristics of such compounds are discussed, and if the appropriate data is available, molecular modes of action are highlighted.
Keywords: Bioorganometallics, cancer chemotherapy, coordination compounds, mode of action, polynuclear complexes, metalloclusters, Polynuclear compounds, trinuclear Pt compound BBR3464, polynuclear ruthenium, osmium and gold complexes, enzyme inhibition, crosslinking, photo-activation, DNA nucleobases, modes of action, Osmium and Gold Complexes
Current Topics in Medicinal Chemistry
Title: Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Volume: 11 Issue: 21
Author(s): Christian G. Hartinger, Andrew D. Phillips and Alexey A. Nazarov
Affiliation:
Keywords: Bioorganometallics, cancer chemotherapy, coordination compounds, mode of action, polynuclear complexes, metalloclusters, Polynuclear compounds, trinuclear Pt compound BBR3464, polynuclear ruthenium, osmium and gold complexes, enzyme inhibition, crosslinking, photo-activation, DNA nucleobases, modes of action, Osmium and Gold Complexes
Abstract: Polynuclear compounds are a relatively new and successful approach in metal-based cancer chemotherapy as typified by the trinuclear Pt compound BBR3464 which was evaluated in clinical trials. In this review, we discuss newer developments of polynuclear ruthenium, osmium and gold complexes, focusing on their anticancer activity. The compounds presented are often supposed to exert their anticancer activity by different modes of action as compared to established drugs, including newly proposed mechanisms such as enzyme inhibition, crosslinking of biomacromolecules or through photo-activation, though many of the examples are also capable of binding to DNA nucleobases. Important metabolization and chemical characteristics of such compounds are discussed, and if the appropriate data is available, molecular modes of action are highlighted.
Export Options
About this article
Cite this article as:
G. Hartinger Christian, D. Phillips Andrew and A. Nazarov Alexey, Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics, Current Topics in Medicinal Chemistry 2011; 11 (21) . https://dx.doi.org/10.2174/156802611798040769
DOI https://dx.doi.org/10.2174/156802611798040769 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Essential Oil-based Microemulsions: Reviewing State-of-the-art
Current Drug Delivery Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design The Patenting and Technological Trends in Cervical Cancer Therapy
Current Biomarkers (Discontinued) Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation
Current Computer-Aided Drug Design Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Intervening Stemness and Angiogenesis in Cervical Carcinoma: Revisiting the Efficacy of Natural Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets